🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Bioventus Inc. (BVS)
NASDAQ: BVS · Real-Time Price · USD
9.88
-0.07 (-0.70%)
Nov 20, 2026, 4:00 PM EST - Market closed

Bioventus Statistics

Total Valuation

Bioventus has a market cap or net worth of $832.50 million. The enterprise value is $1.04 billion.

Market Cap832.50M
Enterprise Value 1.04B

Important Dates

The last earnings date was Monday, November 2, 2026, after market close.

Earnings Date Nov 2, 2026
Ex-Dividend Date n/a

Share Statistics

Bioventus has 84.26 million shares outstanding. The number of shares has increased by 3.97% in one year.

Current Share Class 68.47M
Shares Outstanding 84.26M
Shares Change (YoY) +3.97%
Shares Change (QoQ) +2.34%
Owned by Insiders (%) 2.63%
Owned by Institutions (%) 46.10%
Float 34.06M

Valuation Ratios

The trailing PE ratio is 12.21 and the forward PE ratio is 12.00. Bioventus's PEG ratio is 1.09.

PE Ratio 12.21
Forward PE 12.00
PS Ratio 1.42
Forward PS 1.34
PB Ratio 2.81
P/TBV Ratio n/a
P/FCF Ratio 9.80
P/OCF Ratio 9.52
PEG Ratio 1.09
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.47, with an EV/FCF ratio of 12.28.

EV / Earnings 18.21
EV / Sales 1.78
EV / EBITDA 13.47
EV / EBIT 17.67
EV / FCF 12.28

Financial Position

The company has a current ratio of 1.68, with a Debt / Equity ratio of 0.84.

Current Ratio 1.68
Quick Ratio 1.09
Debt / Equity 0.84
Debt / EBITDA 2.95
Debt / FCF 2.87
Interest Coverage 3.38

Financial Efficiency

Return on equity (ROE) is 25.78% and return on invested capital (ROIC) is 11.65%.

Return on Equity (ROE) 25.78%
Return on Assets (ROA) 5.37%
Return on Invested Capital (ROIC) 11.65%
Return on Capital Employed (ROCE) 11.45%
Weighted Average Cost of Capital (WACC) 7.22%
Revenue Per Employee $610,041
Profits Per Employee $59,683
Employee Count960
Asset Turnover 0.85
Inventory Turnover 2.04

Taxes

Income Tax -24.20M
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +47.02% in the last 52 weeks. The beta is 0.62, so Bioventus's price volatility has been lower than the market average.

Beta (5Y) 0.62
52-Week Price Change +47.02%
50-Day Moving Average 12.81
200-Day Moving Average 11.12
Relative Strength Index (RSI) 28.91
Average Volume (20 Days) 712,495

Short Selling Information

The latest short interest is 3.02 million, so 3.59% of the outstanding shares have been sold short.

Short Interest 3.02M
Short Previous Month 3.18M
Short % of Shares Out 3.59%
Short % of Float 8.88%
Short Ratio (days to cover) 7.30

Income Statement

In the last 12 months, Bioventus had revenue of $585.64 million and earned $57.30 million in profits. Earnings per share was $0.81.

Revenue585.64M
Gross Profit 402.35M
Operating Income 59.05M
Pretax Income 40.13M
Net Income 57.30M
EBITDA 77.49M
EBIT 59.05M
Earnings Per Share (EPS) $0.81
Full Income Statement

Balance Sheet

The company has $33.03 million in cash and $244.15 million in debt, with a net cash position of -$211.12 million or -$2.51 per share.

Cash & Cash Equivalents 33.03M
Total Debt 244.15M
Net Cash -211.12M
Net Cash Per Share -$2.51
Equity (Book Value) 291.87M
Book Value Per Share 3.51
Working Capital 107.84M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $87.43 million and capital expenditures -$2.45 million, giving a free cash flow of $84.99 million.

Operating Cash Flow 87.43M
Capital Expenditures -2.45M
Depreciation & Amortization 18.45M
Net Borrowing -93.25M
Free Cash Flow 84.99M
FCF Per Share $1.01
Full Cash Flow Statement

Margins

Gross margin is 68.70%, with operating and profit margins of 10.08% and 9.78%.

Gross Margin 68.70%
Operating Margin 10.08%
Pretax Margin 6.85%
Profit Margin 9.78%
EBITDA Margin 13.23%
EBIT Margin 10.08%
FCF Margin 14.51%

Dividends & Yields

Bioventus does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -3.97%
Shareholder Yield -3.97%
Earnings Yield 8.19%
FCF Yield 10.21%

Analyst Forecast

The average price target for Bioventus is $16.60, which is 68.02% higher than the current price. The consensus rating is "Strong Buy".

Price Target $16.60
Price Target Difference 68.02%
Analyst Consensus Strong Buy
Analyst Count 5
Revenue Growth Forecast (3Y) 5.77%
EPS Growth Forecast (3Y) 14.00%
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number
Graham Upside
Graham Formula Value
Graham Formula Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Bioventus has an Altman Z-Score of 1.75 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 1.75
Piotroski F-Score 7